Acta Med. 2000, 43: 95-101

https://doi.org/10.14712/18059694.2019.120

Influence of CYP3A Metabolizer Status on the Pharmacokinetics and Pharmacodynamics of Amiodarone

Stanislav Mičudaa, Martin Hodačb, Petr Pařízekb, Miloslav Pleskotb, Luděk Šišperaa, Jaroslav Cermanc, Jana Malákovád, Jiřina Martínkováa, Vladimír Pidrmanb

aCharles University in Prague; Faculty of Medicine in Hradec Králové, Department of Pharmacology, Hradec Králové, Czech Republic
bCharles University in Prague; Faculty of Medicine in Hradec Králové, Second Department of Internal Medicine, Hradec Králové, Czech Republic
cCharles University in Prague; Faculty of Medicine in Hradec Králové, Department of Medical Biochemistry, Hradec Králové, Czech Republic
dUniversity Teaching Hospital in Hradec Králové, Institute of Clinical Biochemistry and Diagnostics, Hradec Králové, Czech Republic

Received March 1, 2000
Accepted June 1, 2000

References

1. Rosenheck S, Sousa J, Calkins H, Schmaltz S, DeBuitleir M, Kadish AH, Morady F. Comparison of the results of electrophysiologic testing after short-term and long term treatment with amiodarone in patients with ventricular tachycardia. Am Heart J 1991; 121:1693-98. <https://doi.org/10.1016/0002-8703(91)90014-9>
2. Kadish AH, Marchlinksi FE, Josephson ME, Buxton AE. Amiodarone: correlation of early and late electrophysiologic studies with outcome. Am Heart J 1986; 112:1134-40. <https://doi.org/10.1016/0002-8703(86)90341-8>
3. Mitchell LB, Wyse G, Gillis AM, Duff HJ. Electropharmacology of amiodarone therapy initiation. Time courses of onset of electrophysiologic and antiarrhythmic effects. Circulation 1989; 80:34-42. <https://doi.org/10.1161/01.CIR.80.1.34>
4. Nattel S. Pharmacodynamic studies of amiodarone and its active N-desethyl metabolite. J Cardiovasc Pharmacol 1986; 8:771-7.
5. Talajic M, DeRoode MR, Nattel S. Comparative electrophysiologic effects of intravenous amiodarone and desethylamiodarone in dogs: Evidence for clinically relevant activity of the metabolite. Circulation 1987; 75:265-71. <https://doi.org/10.1161/01.CIR.75.1.265>
6. Nattel S, Davies M, Quantz M. The antiarrhythmic efficacy of amiodarone and desethylamiodarone, alone and in combination, in dogs with acute myocardial infarction. Circulation 1988; 77:200-8. <https://doi.org/10.1161/01.CIR.77.1.200>
7. Yabek SM, Kato R, Singh BN. Effects of amiodarone and its metabolite, desethylamiodarone, on the electrophysiologic properties of isolated cardiac muscle. J Cardiovasc Pharmacol 1986; 8:197-207. <https://doi.org/10.1097/00005344-198601000-00029>
8. Tieleman RG, Gosselink M, Crijns HJGM, VanGelder I, VandenBerg MP, DeKam PJ, VanGilst WH, Lie KI. Efficacy, safety, and determinants of conversion of atrial fibrillation and flutter with oral amiodarone. Am J Cardiol 1997; 79:53-7. <https://doi.org/10.1016/S0002-9149(96)00675-3>
9. Fabre G, Julian B, Saint-Aubert B, Joyeux H, Berger Y. Evidence for CYP3A-mediated N-deethylation of amiodarone in human liver microsomal fractions. Drug Metab Dispos 1993; 21:978-85.
10. Rendic S, DiCarlo FJ. Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers and inhibitors. Drug Metab Rev 1997; 29:413-580. <https://doi.org/10.3109/03602539709037591>
11. Shimada T, Yamazaki H, Mimura M, Inui Y, Guengerich FP. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 1994; 270:414-23.
12. Lown KS, Thummel KE, Benedict PE, Shen DD, Turgeon DK, Berent S, Watkins PB. The erythromycin breath test predicts the clearance of midazolam. Clin Pharmacol Ther 1995; 57:16-24. <https://doi.org/10.1016/0009-9236(95)90261-9>
13. Watkins PB. Noninvasive test of CYP3A enzymes. Pharmacogenetics 1994; 38:82-9.
14. Thummel KE, O’Shea D, Paine MF, Shen DD, Kunze KL, Perkins JD, Wilkinson GR. Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-mediated metabolism. Clin Pharmacol Ther 1996; 59:491-502. <https://doi.org/10.1016/S0009-9236(96)90177-0>
15. Ohnhaus EE, Park BK. Measurement of urinary 6-beta-hydroxycortisol excretion as an in vivo parameter in the clinical assessment of the microsomal enzyme-inducing capacity of antipyrine, phenobarbitone and rifampicin. Eur J Clin Pharmacol 1979; 15:139-45. <https://doi.org/10.1007/BF00609878>
16. Ohnhaus EE, Breckeridge AM, Park BK. Urinary excretion of 6β-hydroxycortisol and the time course measurement of enzyme induction in man. Eur J Clin Pharmacol 1989; 36:39-46. <https://doi.org/10.1007/BF00561021>
17. Tomlinson B, Young RP, Ng MCY, Anderson PJ, Kay R, Critchley JAJH. Selective liver enzyme induction by carbamazepine and phenytoin in Chinese epileptics. Eur J Clin Pharmacol 1996; 50:411-5. <https://doi.org/10.1007/s002280050132>
18. Park BK. Assessment of urinary 6β-hydroxycortisol as in vivo index of mixed function oxygenase activity. Br J Clin Pharmacol 1981; 12:97-102. <https://doi.org/10.1111/j.1365-2125.1981.tb01186.x> <PubMed>
19. Zürcher RM, Frey BM, Frey FJ. Impact of ketoconazole on the metabolism of prednisolon. Clin Pharmacol Ther 1989; 45:366-72. <https://doi.org/10.1038/clpt.1989.42>
20. Saenger P. 6β-Hydroxycortisol in random urine samples as an indicator of enzyme induction. Clin Pharmacol Ther 1983; 34:818-21. <https://doi.org/10.1038/clpt.1983.255>
21. Pleskot M, Pařízek P, Hodač M, Haman L, Štásek J, Červinka P, Tauchman M. Revascularization of the myocardium and electrical instability of the ventricles. Vnitř Lék 1999; 45:75-80.
22. Lee CH. Urinary 6β-hydroxycortisol in humans: analysis, biological variations, and reference ranges. Clin Biochem 1995; 28:49-54. <https://doi.org/10.1016/0009-9120(94)00060-9>
23. Kopecká J, Palička V. Liquid-chromatographic determination of amiodarone and N-desethylamiodarone in serum. Ninth Conference of Young Biochemists in Jánské Lázně, May 20-22, 1996.
24. Kovacs SJ, Martin DE, Everitt DE, Patterson SD, Jorkasky DK. Urinary excretion of 6β-hydroxycortisol as in vivo marker for CYP3A induction: applications and recommendations. Clin Pharmacol Ther 1998; 63:617-22. <https://doi.org/10.1016/S0009-9236(98)90084-4>
25. Beyeler C, Frey BM, Bird HA. Urinary 6β-hydroxycortisol excretion in rheumatoid arthritis. Br J Rheumatol 1997; 36:54-8. <https://doi.org/10.1093/rheumatology/36.1.54>
26. Kinirons MT, O’Shea D, Kim RB, Groopman JD, Thummel KE, Wood AJJ, Wilkinson GR. Failure of erythromycin breath test to correlate with midazolam clearance as a probe of cytochrome P4503A. Clin Pharmacol Ther 1999; 66:224-31. <https://doi.org/10.1016/S0009-9236(99)70029-9>
27. Seidegard J, Dahlstrom K, Kullberg A. Effect of grapefruit juice on urinary 6β-hydroxycortisol/cortisol excretion. Clin Exp Pharm Physiol 1998; 25:379-81. <https://doi.org/10.1111/j.1440-1681.1998.tb02366.x>
28. Wrighton SA, Brian WR, Sari MA, Iwasaki M, Guengerich FP, Raucy JL. Studies on the expression and metabolic capabilities of human liver cytochrome P450IIIA5 (HLp3). Mol Pharmacol 1990; 38:207-13.
29. Wrighton SA, Ring BJ, Watkins PB, VanderBranden M. Identification of a polymorphically expressed member of the human cytochrome P-450III family. Mol Pharmacol 1989; 36:97-105.
30. Murray GI, Barnes TS, Sewell HF. The immunocytochemical localisation and distribution of cytochrome P-450 in normal human hepatic and extrahepatic tissues with a monoclonal antibody to human cytochrome P-450. Br J Clin Pharmacol 1988; 25:465-75. <https://doi.org/10.1111/j.1365-2125.1988.tb03331.x> <PubMed>
31. Schuetz EG, Schuetz JD, Grogan WM, Naray A, Fejes AG, Toth AG, Raucy J. Expression of cytochrome P4503A in amphibian rat and human kidney. Arch Biochem Biophys 1992; 294:206-14. <https://doi.org/10.1016/0003-9861(92)90159-T>
32. Watkins PB, Turgeon DK, Saenger P. Comparison of urinary 6β-cortisol and the erythromycin breath test as measures of hepatic P450IIIA (CYP3A) activity. Clin Pharmacol Ther 1992; 52:265-73. <https://doi.org/10.1038/clpt.1992.140>
33. Ged C, Rouillon JM, Pichard L. The increase in urinary excretion of 6β-hydroxycortisol as a marker of human hepatic cytochrome P450 IIIA induction. Br J Clin Pharmacol 1989; 28:373-87. <https://doi.org/10.1111/j.1365-2125.1989.tb03516.x> <PubMed>
34. Mostow ND, Rakita L, Vrobel TR, Noon DL, Blumer J. Amiodarone: correlation of plasma concentration with suppression of complex ventricular ectopic activity. Am J Cardiol 1984; 54:569-74. <https://doi.org/10.1016/0002-9149(84)90250-9>
35. Roden DM. Pharmacokinetics of amiodarone: implications for drug therapy. Am J Cardiol 1993; 72:45F-50F. <https://doi.org/10.1016/0002-9149(93)90962-C>
36. Falik R, Flores BT, Shaw L, Gibson GA, Josephson ME, Marchlinski FE. Relationship of steady-state serum concentrations of amiodarone and desethylamiodarone to therapeutic efficacy and adverse effects. Am J Med 1987; 82:1102-8. <https://doi.org/10.1016/0002-9343(87)90211-7>
37. Brennan FJ, Brien JF, Armstrong PW. Plasma concentration time course and pharmacological effects of a standardized oral amiodarone dosing regimen in humans. Can J Cardiol 1991; 7:117-24.
38. Evans SJL, Myers M, Zaher C, Simonson J, Nalos P, Vaughn C, Oseran D, Gang E, Peter T, Mandel W. High dose oral amiodarone loading: electrophysiologic effects and clinical tolerance. J Am Coll Cardiol 1992; 19:169-73. <https://doi.org/10.1016/0735-1097(92)90069-Y>
39. Holt DN, Storey GCA, McKenna WJ, Adams PC, Campbell RWF. Unwanted effects of amiodarone in relation to tissue concentration. J Am Coll Cardiol 1983; 1:630-9.
40. Haffajee CI, Love JC, Alpert JS, Asdourian GK, Sloan KC. Efficacy and safety of long-term amiodarone in treatment of cardiac arrhythmias: dosage experience. Am Heart J 1983; 106:935-43. <https://doi.org/10.1016/0002-8703(83)90019-4>
front cover

ISSN 1211-4286 (Print) ISSN 1805-9694 (Online)

Open access journal

Archive